Toripalimab management
death
DISEASE PROGRESSION, TUMOR PROGRESSION, ADVERSE REACTION, EVENT
Anti‐PD‐1 infusion (anti‐PD‐1 240 mg Q3W * 4 doses) will be administered within 7–10 days after RFA treatment and continued until the occurrence of an intolerable immune adverse reaction, completion of 4 doses, or tumor progression. After receiving the treatment, patients will return to the hospital for follow‐up at 1 month, 3 months, 6 months, and then every 3 months until the protocol‐specified treatment discontinuation event occurs. Subjects who discontinue treatment for reasons other than disease progression or death will also be monitored for tumor progression at the end of treatment.